Comparison of Ixekizumab and Ustekinumab Efficacy in the Treatment of Nail Lesions of Patients With Moderate-to-Severe Plaque Psoriasis: 52-Week Data From the IXORA-S Trial

2018 ◽  
Vol 2 ◽  
pp. S117
Author(s):  
Norman Wasel ◽  
Yves Dutronc ◽  
Birgit Schinzel ◽  
Jean-Philippe Lacour
Keyword(s):  
Plaque Psoriasis ◽  
Severe Plaque Psoriasis

Abstract not available. Disclosures: Study sponsored by Eli Lilly & Company. Copyright 2018 SKIN

Evaluation of the PGAxBSA Composite Tool in Patients with Moderate-to-Severe Plaque Psoriasis

2017 ◽  
Vol 1 ◽  
pp. s14
Author(s):  
Kristina Callis Duffin ◽  
J Mark Jackson ◽  
Joana Goncalves ◽  
Eugenia Levi ◽  
Jerry Bagel
Keyword(s):  
Plaque Psoriasis ◽  
Severe Plaque Psoriasis ◽  
Composite Tool

Abstract Not Available Disclosure: Study supported by Celgene.

Pharmacoeconomic analysis of using genetically engineered biologic drugs for treating adult patients with moderate to severe plaque psoriasis in the Russian Federation

2020 ◽  
pp. 57-65
Author(s):  
Maksim Frolov ◽  
Vladimir Rogov ◽  
Alla Salasyuk
Keyword(s):  
Plaque Psoriasis ◽  
Impact Analysis ◽  
Pharmacoeconomic Analysis ◽  
Certolizumab Pegol ◽  
Genetically Engineered ◽  
Adult Patients ◽  
Comparable Efficacy ◽  
Biologic Drugs ◽  
Severe Plaque Psoriasis ◽  
Cost Minimisation Analysis

The aim of the study was to assess clinical and economic effectiveness of netakimab compared to other genetically engineered biologic drugs (infliximab, adalimumab, etanercept, ustekinumab, secukinumab, ixekizumab, certolizumab pegol) for the treatment of adult patients with moderate to severe plaque psoriasis. We have conducted cost-benefit analysis, cost-minimisation analysis, and budget impact analysis. We have considered only direct medical costs. The results of the study show that netakimab has higher or comparable efficacy and significantly lower costs compared to other biologic drugs, that makes it the most preferable treatment option for patients with moderate to severe plaque psoriasis. Use of netakimab in clinical practice will significantly reduce budget expenditures and increase patient access to biologic therapy.

Sign in / Sign up

Export Citation Format

Share Document